Introduction {#s1}
============

The binding of proteins, peptides, enzymes, antibody fragments, oligonucleotides, or small synthetic drugs to polymers has become a very useful method for improving therapeutic activity or decreasing the toxicity of these biological agents ([@B116]). Among the polymeric materials, polyethylene glycol (PEG) is the most used for these purposes, mainly due to its high biocompatibility, low toxicity, and limited side effects ([@B47]). PEGs are water-soluble polymers approved by the Food and Drug Administration for use in oral, topical, and intravenous formulations ([@B29]). It presents a structure of repeated units of polyether diols (either linear or branched) chemically formulated as HO-(CH~2~CH~2~O)n-CH~2~CH~2~-OH ([**Figure 1A**](#f1){ref-type="fig"}), where each ethylene oxide residue has a molecular weight (MW) of 44 Da ([@B146]). PEGylation refers to the covalent or non-covalent attachment of PEG to different molecules, such as proteins, macromolecular carriers, oligonucleotides, vesicles, and others to improve the pharmacokinetic ([@B114]; [@B93]) and pharmacodynamic properties ([@B1]). The conjugation to PEG generates an increase in the hydrodynamic volume of the biomolecule of interest, creating a shield around it ([@B54]). This effect enables clearance by the renal system to be reduced, and therefore, the half-life is increased in the bloodstream ([@B113]) concomitant with the increases in PEG molecular weight ([@B59]). Additionally, this approach has been used to improve the stability of some proteins ([@B203]; [@B70]; [@B91]; [@B152]), as well as decrease the immune response against several biomolecules ([@B165]; [@B210]; [@B154]; [@B196]).

![A general scheme of protein PEGylation at N-terminus. **(A)** PEG chemical structure based on linear polyethylene oxide repeating units. **(B)** Schematic representation of the N-terminal PEGylation reaction. The square represents PEG functional group that covalently binds to the terminal amine of the protein. PEG chain is end-capped with a terminal methoxy group to prevent reactivity and enzymatic attack upon administration in mammals.](fphar-10-01450-g001){#f1}

Since the 1990s several PEGylated biopharmaceuticals (see [**Table 1**](#T1){ref-type="table"}) have been approved by the FDA, and some more are currently undergoing clinical trials (information available at <https://clinicaltrials.gov/ct2/results?term=Pegylated&Search=Apply&recrs=d&age_v=&gndr=&type=&rslt=>). Most of the approved PEGylated proteins were synthesized by non-site-specific chemical conjugation strategies, resulting in heterogeneous mixtures of multi-PEGylated (polydisperse) proteins due to the presence of several reactivity sites on the protein surface ([@B4]), requiring complex separation steps. In addition, protein PEGylation can lead to the loss of protein activity through several mechanisms that include the direct PEGylation of the active site or receptor binding site ([@B157]), the steric entanglement imposed by PEG chains that cause restricted movements ([@B84]; [@B199]) and conformational changes in proteins ([@B27]), among others. Also, recent research has revealed certain shortcomings related to highly PEGylated forms, such as activation of the immune system, non-degradability, and possible accumulations with high molecular weight PEGs. These are strong reasons that support the need to find site-selective PEGylation techniques, yielding homogenous mono-PEGylated products, a field that has garnered considerable in recent years. Although certainly the *in vivo* potency of therapeutic proteins can be affected by the PEGylation process, this decrease in activity can be largely balanced by their prolonged half-life in the circulation ([@B132]). Site-selective PEGylation has been a very useful strategy for introducing PEG at specific amino acid sites in various proteins. Some methods like pH-controlled N-terminal selective acylation ([@B22]; [@B23]) or reductive alkylation ([@B78]; [@B108]), the use of oxidizing agents ([@B85]; [@B131]), the chemo-selective capability of catechol ([@B166]) and transamination reaction ([@B51]) have been used to perform PEGylation at the N-terminus of proteins. Additionally, in recent years there has been a lot of work on using "grafting from" approaches to grow PEG from the surface of proteins *via* ATRP and RAFT polymerization methods ([@B141]; [@B6]; [@B53]; [@B179]). These approaches involve the direct generation of conjugates containing high molecular weight polymers (like PEGs) by directly growing the polymer from the protein surface ([@B185]; [@B130]).

###### 

PEGylated therapeutic peptides and proteins approved for clinical applications.

  Product names                    PEGylated drugs                                                         Sites of Attachment                                PEG sizes               Indications                                                        Manufacturers                                        References
  -------------------------------- ----------------------------------------------------------------------- -------------------------------------------------- ----------------------- ------------------------------------------------------------------ ---------------------------------------------------- ------------------
  PEG-ADA (Adagen^®^)              PEGylated bovine adenosine deaminase                                    Lysines, N-terminal                                5 kDa                   Imunodeficiency disease caused by adenosine deaminase deficiency   Enzon Pharmaceuticals Inc., USA                      ([@B89]; [@B4])
  PEGASPARGASE (Oncaspar^®^)       PEGylated L-asparaginase                                                Lysines, serine, tyrosine,hystidine                5 kDa                   Acute lymphoblastic leukemia                                       Enzon Pharmaceuticals Inc., USA                      ([@B38])
  PEGVISOMANT (Somavert^®^)        PEGylated recombinant receptor antagonist of the human growth hormone   Lysines 38,120,140,158, N-terminal phenylalanine   5 kDa (4--6 units)      Acromegaly                                                         Pharmacia & Upjohn Company LLC., USA                 ([@B80]; [@B4])
  PEG-INTRON^®^                    PEGylated interferon alfa-2b                                            Hystidine 34 (major)                               12 kDa                  Chronic hepatitis C                                                Schering-Plough Corporation, USA                     ([@B188]; [@B4])
  PEGASYS^®^                       PEGylated interferon alfa-2a                                            Lysines 31, 121, 131, or 134                       40 kDa                  Chronic hepatitis C & B                                            Hoffmamn-La Roche Inc., USA                          ([@B43])
  CERTOLIZUMAB PEGOL (Cimzia^®^)   PEGylated tumor necrosis factor alpha inhibitor                         C-Terminal cysteine                                40 kDa                  Crohn's disease                                                    UCBPharma, Belgium                                   ([@B58])
  PEGFILGRASTIM (Neulasta^®^)      PEGylated granulocyte colony-stimulating factor analog                  N-Terminal methionine                              20 kDa                  Neutropenia during chemotherapy                                    Amgen Inc., USA                                      ([@B120])
  PLEGRIDY^®^                      PEGylated β-interferon 1a                                               N-terminal                                         20 kDa                  Multiple sclerosis                                                 Biogen Idec, USA                                     ([@B180])
  PEGLOTICASE (Krystexxa^®^)       PEGylated urate oxidase                                                 Lysines                                            10 kDa (10--11 units)   Chronic gout                                                       Horizon Pharmaplc, Dublin                            ([@B4]; [@B103])
  Mircera^®^                       PEGylated erythropoietin receptor activator                             Lysine 52 or 46                                    30 kDa                  Anemia associated with chronic kidney disease                      Roche Inc., USA                                      ([@B15])
  Sylatron^®^                      PEGylated interferon alfa-2b                                            C-terminal cysteine                                12 kDa                  Adjuvant therapy in resected stage III melanoma                    Merck Sharp & Dohme Corp, USA                        ([@B116])
  PEGINESATIDE\*\* (Omontys^®^)    PEGylated synthetic peptide, erythropoietin analogs                     Lysines                                            40 kDa                  Anemia associated with chronic kidney disease                      Affymax Inc, USA & Takeda Pharmaceutical Co, Japan   ([@B170])

\*\*Recalled from the market on 2013 due to hypersensitivity.

An illustrative example of success in chemical site-selective PEGylation is the case of Neulasta^®^, which is an N-terminally mono-PEGylated granulocyte colony-stimulating factor bearing a 20-kDa PEG ([@B120]). The improved pharmacokinetic behavior of this biopharmaceutical allows administration only once per chemotherapy cycle compared to the first generation, Neupogen^®^, which is administered daily ([@B21]; [@B207]).

Despite their robustness, chemical methods usually involve the use of excessive amounts of reagents and careful working conditions. Site-specific PEGylation of peptides and proteins has been approached successfully not only from the chemical point of view but also enzymatically. Several studies report the use of enzymes to conjugate PEG to peptides, proteins, and oligonucleotides ([@B155]; [@B110]; [@B30]; [@B167]).These enzymes usually catalyze the reaction between the biomolecule of interest and a substrate analog containing a functional group ([@B35]), which can be the case of PEG. There are a number of more recent approaches aimed at achieving site-selective modification including the use of the Spytag/Spycatcher system ([@B159]; [@B144]; [@B19]; [@B77]); however, there is as yet insufficient information focused on these methods, and some studies are being developed in this direction.

The structural changes in protein characteristics after the attachment to PEG influence the subsequent characterization of PEGylated proteins. These changes result in an analytical challenge due to the heterogeneity of the PEGylation products and the degree of PEGylation, coupled with the complex protein structure ([@B68]). Several studies have reported the use of analytical techniques with differing degrees of difficulty---from colorimetric methods to more complex techniques such as computational approaches---for the characterization of PEGylated peptides and proteins.

In the present review, we have focused on summarizing both classic and novel chemical and enzymatic tools used for the covalent attachment of PEG in site-specific regions of peptides and proteins, as well on the main analytical methods for PEGylated molecule characterization.

Chemical Approaches for Site-Selective Pegylation {#s1_1}
-------------------------------------------------

For the selective modification of specific amino acids in peptides and proteins, the knowledge of some characteristics about their primary structure is needed. An important physicochemical feature in proteins is the difference in pKa between the amino group of an N-terminal amino acid residue (∼7.6) and the amino groups in the side chains of lysine (∼10.5) and arginine (∼12) ([@B146]). This difference allows the selective N-terminal modification of proteins based on pH control and the use of reductive agents like sodium cyanoborohydride. A useful strategy for the specific conjugation of peptides and proteins is based on the amino acid ratio in a protein being variable. Moelbert et al. reported the accessibility index on the surface of the 20 essential amino acids, which makes it possible to know the expression of these amino acids in different areas of the proteins in relation to their natural abundance ([@B119]). It has also been reported that short peptides/proteins (less than 50 residues) tend to over-represent glutamine and cysteine in the N-terminal region ([@B184]). It is well known that single-chain proteins possess only one N-terminal residue, having a uniquely reactive site for chemical modification ([@B147]). Therefore, as virtually all proteins present these functional groups, a number of valuable reactions have been developed for their selective modification ([@B8]).

The use of potassium ferricyanide as an oxidizing agent in o-aminophenol-performing N-terminal PEGylation has also been shown ([@B131]). In 2016 Song et al. described an alternative strategy for PEGylation at the N-terminus of several proteins as well as two peptides based on the chemoselectivity of catechol ([@B166]). More recently, Rosen and Francis described classical methods for the selective modification of N-terminal amino group under pH control. These methods include the selective acylation and alkylation of N-terminal amines at low-to-neutral pH and also transamination using pyridoxal-5′-phosphate aldehyde, which undergoes condensation with ε-amines from lysine side chains and N-terminal α amines to form imines ([@B51]; [@B147]). Chen et al. demonstrated the ability of benzaldehyde to selectively modify native peptides and proteins on their N-termini. Preservation of the positive charge on the N-terminus of the human insulin A-chain through reductive alkylation instead of acylation leads to a 5-fold increase in bioactivity. They showed that under mild conditions, aldehyde derivatives and carbohydrates can site-specifically react with peptide and protein N-termini, providing a universal strategy for site-selective N-terminal functionalization in native peptides and proteins ([@B25]).

PEG-isocyanate is in the group of PEG reagents used for the site-specific modification of different proteins ([@B7]; [@B162]). The reaction takes place *via* the amine group to produce a stable thiourea linkage ([@B46]). For example, in 2009 Cabrales et al. generated PEGylated human serum albumin (PEG-HSA) by conjugating PEG-phenyl-isothiocyanate 3 and 5 kDa at primary amine groups of the HSA, enhancing the hydrodynamic volume of the protein and restoring intravascular volume after hemorrhagic shock resuscitation ([@B14]). Furthermore, Chen and He reported in 2015 the achievement of nanophosphors coated with PEG-isocyanate and polylactic acid (PLA) for paclitaxel delivery, resulting in a significant improvement and serving as a platform in the field of drug development ([@B24]). Lee et al. synthesized a dual functional cyclic peptide gatekeeper attached on the surface of nanocontainers by using PEG-isocyanate as a linker to enhance dispersion stability and biocompatibility. This allowed the active targeting of cancer cells with high CD44 expression together with the ability of triggered drug release ([@B95]). It is important to note that specific PEG-reagents like isocyanates have a short half-life in aqueous solutions ([@B37]); thus, a stoichiometric excess of these reagents is necessary, causing difficulties in the removal of the remaining PEG.

A relevant report for one-step N-terminus-specific protein modification showed the stable and selective imidazolidinone product at the N-terminus, with 2-pyridinecarboxaldehyde (2PCA) derivatives ([@B105]). The main basis of this reaction is the nucleophilic attack of the neighboring amide nitrogen on the electrophilic carbon of the initially formed N-terminal imine ([@B81]). As an example, a 2PCA-functionalized polyacrylamide-based hydrogel has been developed for the immobilization of extracellular matrix proteins through the N-terminus to study their biochemical and mechanical influence on cells ([@B94]).

In the next section, we provide an overview based on reactions which can be used to selectively modify specific amino acids. Keeping that in mind, in some cases the described modification does not refer to the PEGylation itself, but the concept could be applied if the introduction of PEG reagents is desired. A mechanism corresponding to N-terminal PEGylation has been illustrated in [**Figure 1B**](#f1){ref-type="fig"}, while general mechanisms of the site-selective chemical reactions are shown in [**Figure 2**](#f2){ref-type="fig"}.

![Schematic representation of chemical reactions described for the selective PEGylation of proteins.](fphar-10-01450-g002){#f2}

Strategies for the Modification of Specific Amino Acids {#s1_2}
-------------------------------------------------------

### Targeting Cysteine {#s1_2_1}

Cysteine residues are interesting targets for residue-specific modification of peptides/proteins due to their low apparition frequency ([@B61]). These are often found partially or fully covered within the protein structure, limiting their accessibility to chemical reagents ([@B174]). Proteins with N-terminal cysteine have been successfully modified through native chemical ligation (NCL) when, on the first and reversible step, a thioester intermediate is formed, which then undergoes a spontaneous S-to-N acyl shift and yields an amide bond ([@B71]; [@B147]). This methodology has been useful in the preparation of high complexity protein--polymer conjugates. For example, Zhao et al. described a PEGylated human serum albumin (HSA) in a site-specific method by taking advantage of the unusual chemical reactivity of the only one free Cys34 of the HSA molecule and the high specificity of PEG-maleimide for the protein sulfhydryl (-- SH) groups. Targeting the distinctive free Cys34 through this site-specific PEGylation could generate a chemically well-defined and molecularly homogeneous product and may be also convenient in preventing dimerization ([@B209]). Another technique which plays a major role in modern chemical biology and has been used for many applications is known as expressed protein ligation (EPL) ([@B117]; [@B31]; [@B101]). EPL constitutes an improvement for NCL, and in this case selectivity over lysine acylation was achieved through pH control, by using benzaldehyde derivatives bearing selenoesters to acylate N-terminal positions through acyl transfer ([@B143]).

As N-terminal cysteines are rare in nature, they frequently need to be introduced by genetic engineering ([@B126]; [@B181]; [@B58]). Methionine aminopeptidase can take out the first methionine to liberate an N-terminal cysteine ([@B48]), and some proteolytic enzymes that specifically cleave in the presence of cysteine residues in a protease recognition sequence ([@B13]; [@B194]) have been used as strategies for the exposure of N-terminal cysteine and its subsequent bioconjugation.

### Targeting Serine and Threonine {#s1_2_2}

The presence of an N-terminal serine or threonine offers unique opportunities due to the high susceptibility of 1, 2-aminoalcohols to periodate oxidation, resulting in the formation of a glyoxylyl group, which can be used to form several linkages ([@B197]). It has been shown that the extra periodate used to oxidize the N-terminal residues of proteins carries the risk of oxidizing other residues, such as cysteines and methionines, as well as causing unwanted oxidative cleavage of protein glycosyl groups ([@B66]). This is mainly the approach applied in classical research, based on targeting serines or threonines at the N-terminal position, which uses periodate oxidation to generate a glyoxylyl group. Gaertner et al. performed site-selective PEGylation of an N-terminal serine residue, which was oxidized using sodium periodate followed by subsequent oxime ligation with an aminooxy and hydrazyde PEG derivative ([@B44]). The modified proteins, interleukin (IL)-8, granulocyte colony-stimulating factor (G-CSF) and IL-1rα, fully retained their activity after PEGylation ([@B83]).

### Targeting Tyrosine {#s1_2_3}

Francis et al. Have Reported a Number of Efficient strategies where tyrosine residues were modified *via* a three-component Mannich-type reaction, alkylation of the residue and coupling with diazonium reagents ([@B176]). However, Jones et al. were the first to describe direct polymer conjugation, including PEGylation, to tyrosine residues. These authors developed a general route to polymer-peptide biohybrid materials by preferentially targeting peptide tyrosine residues using diazonium salt-terminated polymers. Also, aniline derivatives are attractive molecules for tyrosine-targeted protein modifications with 4-aminobenzoyl-N-PEG~2000~-OMe through either diazonium coupling or three-component Mannich-type reactions ([@B73]). Recently, the first study to apply Mannich reaction modification and reactive coloration in fibrous proteins was developed, providing promising future applications for the reactive dyeing process of silk ([@B26]).

### Targeting Tryptophan {#s1_2_4}

Peptides containing N-terminal tryptophan residues may be modified using the Pictet-Spengler reaction with aldehydes in glacial acetic acid. The Pictet-Spengler reaction is based on the oxidation of the N-terminal amino group to an imine, where an aldehyde undergoes cyclic condensation with the α-amine and the indole side chain of a tryptophan residue, forming a new stable C--C bond ([@B3]; [@B118]). Li et al. applied the Pictet-Spengler reaction to peptide ligation using peptide segments containing an aldehyde at the C-terminal and a Trp at the N-terminal. The main advantage of this reaction is the formation of a product with a stable C--C bond in a single step ([@B97]). Also, Sasaki et al. applied the Pictet-Spengler reaction to the N-terminal labeling of horse heart myoglobin with an N-terminal glycine, employing tryptophan methyl ester and tryptamine as the coupling partners ([@B153]).

As an alternative to chemoselective modification, recombinant methods have also been used to incorporate unnatural amino acids (UAA) into proteins as chemical handles for a bio-orthogonal conjugation reaction ([@B100]). The transfer of non-natural amino acids with azide and ketone functional groups at the N-terminus of proteins bearing N-terminal arginine residues using leucyl/phenylalanyl (L/F)-tRNA-protein transferase has proven efficient, both in the presence of other peptides and in crude protein mixture ([@B173]). Although considerable progress has been made, an improvement in the existing N-terminal strategies is needed as none of the methods reported to date offer universal sequence compatibility.

Enzymatic Tools for Selective Pegylation of Proteins {#s2}
====================================================

Enzyme-mediated bioconjugation has gained a lot of attention in recent years because of the ability of biocatalysts to modify specific molecular tags under mild conditions. In this section, we briefly explore some enzymatic tools used for selective PEGylation purposes. Among these, *sortase A* (SrtA) from *Staphylococcus aureus* has been the most widely applied enzyme for protein bioconjugation in academic research ([@B178]; [@B137]; [@B158]; [@B191]). It catalyzes a transpeptidase reaction between an N-terminal amino group derived from glycine and a specific internal amino acid sequence on a protein, usually LPXTG (where X can be any amino acid) ([@B147]) ([**Figure 3A**](#f3){ref-type="fig"}). Although the *sortase A* is applied for labeling the peptides and proteins among them, the approach of *sortase*-mediated PEGylation has been used to label large macroscopic particles with PEG-stabilized proteins to the surface of cells ([@B177]). More recently, Li et al. took advantage of the mutated *sortase A* enzyme, which can enzymatically ligate the universal α-amino acids to a C-terminal tagged protein, allowing specific modification of the C-terminus of human growth hormone (hGH) with PEG. This site-specific bound PEG-hGH has similar efficacy as wild-type hGH ([@B164]). Despite there being as yet no approved PEGylated drugs derived from sortagging, it could be a promising advancement for improving the performance of traditional PEGylated drugs.

![Enzyme-mediated modification of proteins. The (x) and (a) locked in circles represent hypothetical amino acids.](fphar-10-01450-g003){#f3}

Microbial Transglutaminases {#s2_1}
---------------------------

Microbial transglutaminases (mTGases) are another class of enzymes that has frequently been used for protein conjugation ([**Figure 3B**](#f3){ref-type="fig"}). Several excellent reviews covering applications of microbial transglutaminase have been published previously ([@B107]; [@B142]; [@B2]; [@B171]). In general terms, TGases catalyze the acyl transfer reaction between the c-carboxyamide group of a protein-bound Gln residue and a variety of linear primary amines, such as the amino group of Lys ([@B57]). In terms of site selective PEGylation this approach could be ineffective due to promiscuity in the amine substrates for these enzymes ([@B142]). Nevertheless, Pasut et al. examined how the properties of PEGylated human growth hormone (hGH) changed depending on whether it was generated by chemical modification at the N-terminus or enzymatically using transglutaminase. Enzymatic labeling of hGH was carried out using TGase and a PEG reagent incorporating a primary amine. The study shows that although hGH carries 13 glutamine residues, 63.3% of the reaction product was a monoPEGylated form at position 141, showing a certain degree of site selectivity ([@B30]). Spolaore et al. studied the reactivity of IFN α-2b to microbial mTGase to obtain a site-specific conjugation of this biopharmaceutical. Characterization by mass spectrometry of the conjugates indicated that among the 10 Lys and 12 Gln residues of the protein only Gln101 and Lys164 were selectively conjugated with a PEG-NH~2~ for Gln101 and a PEG modified with carbobenzoxy\--glutaminyl-glycine for Lys164 derivatization, with activity retention and improvements at pharmacokinetic levels ([@B169]). A mono-PEGylated derivative of filgrastim (granulocyte colony-stimulating factor) was also prepared using mTGase. The conjugation yielded an active protein with a single conjugation site (Gln135) that exhibited good *in vivo* stability ([@B156]). Although in the previous examples the PEGylation sites do not correspond to the N-terminal amino acid, they do illustrate a partial selectivity of mTGase despite its tendency toward substrate promiscuity. Also, these results indicate the potential of mTGase in the future of specific PEGylation and the development of innovative biopharmaceuticals. More recently, Braun et al. obtained an insulin-like growth factor 1-PEG (IGF1-PEG) conjugate for release in diseased tissue by using a combination of enzymatic and chemical bio-orthogonal coupling strategies. In this interesting example, mTGase was used for the ligation at the level of the N-terminal lysine of IGF1 to a PEG30 kDa modified protease-sensitive linker ([@B10]).

Subtiligase {#s2_2}
-----------

Subtiligase is a redesigned peptide ligase based on the modification of the active site of subtilisin. It was engineered by converting catalytic Ser221 to Cys, thereby increasing the ligase activity compared to amidase activity, and Residue Pro225 was converted to Ala to reduce steric assembling ([@B60]). Subtiligase facilitates the ligation between a peptide C-terminal ester and a peptide N-terminal α-amine, without requiring a recognition motif at the termini of any reaction partners ([@B99]) ([**Figure 3C**](#f3){ref-type="fig"}). The selective modification of the α-amine using subtiligase is a powerful approach in proteomics to enrich new N-termini arising from protease recognition and cleavage ([@B193]), because 80% and 90% of wild-type eukaryotic proteins are acetylated at the N-terminal position ([@B136]). This advantage could be exploited for the selective attachment of PEG-modified peptides as an innovative application to improve either the conjugation efficiency or the originality in the development of therapeutics.

### Butelase 1 {#s2_2_1}

Butelase 1 is an enzyme isolated from the medicinal and ornamental plant *Clitoria ternatea,* which is a high-yielding asparagine/aspartate-specific cysteine ligase ([@B127]) ([**Figure 3D**](#f3){ref-type="fig"}). In spite of being C-terminal-specific for Asx, this enzyme accepts most N-terminal amino acids to mediate intermolecular peptide and protein ligation ([@B129]). Although it was recently discovered, *butelase 1* has been used for several purposes, such as protein modification and engineering, peptide/protein ligation and labeling, peptide/protein macrocyclization, and living-cell surface labeling ([@B99]). No work has yet reported *butelase 1* as being used for PEGylation reactions. However, some recent experiences with the enzyme, such as the method developed by Nguyen et al. for butelase-mediated ligation using thiodepsipeptides, have been applied in N-terminal labeling of ubiquitin and green fluorescent protein (GFP). The ligation yield of \> 95% could be achieved for the model peptide and ubiquitin with a small substrate excess. This result anticipates a wide-ranging application and the perspectives of using *butelase 1* for N-terminal modification of peptides and proteins ([@B128]).

Lipoid Acid Ligase {#s2_3}
------------------

Lipoid acid ligase (LplA) is an alternative enzyme that has also been exploited for protein bioconjugation. This enzyme is able to recognize a specific LplA acceptor peptide (LAP) and catalyze the attachment of a lipoate moiety to a lysine residue in LAP (GFEIDKVWYDLDA) through an ATP-dependent reaction ([@B138]; [@B208]) ([**Figure 3E**](#f3){ref-type="fig"}). Regarding PEGylation, Plaks et al. used LplA for multisite clickable modification based on the incorporation of azide moieties in GFP at the N-terminal and two internal sites. Modification of the ligated azide groups with PEG, α\--mannopyranoside and palmitic acid resulted in highly homogeneous populations of conjugates, being a potential approach, for instance, for site-specific multipoint protein PEGylation, among other modifications ([@B135]). Additionally, other studies have been conducted using LplA-mediated enzymatic protein labeling followed by subsequent bio-orthogonal reactions ([@B62]; [@B36]; [@B56]), allowing site-specific labeling of N- or C-terminus, even at the internal regions of a target protein.

There are other enzymes that have also been exploited for protein bioconjugation, including tubulin tyrosine ligase, which catalyzes the ATP-dependent addition of a tyrosine residue to the C-terminus of a-tubulin yielding a peptide bond ([@B161]; [@B208]); N-myristoyltransferase, leading the transference of myristate from myristoyl-CoA to the N-terminal glycine of protein substrates, resulting in an amide linkage ([@B195]; [@B208]); and biotin ligase, another ATP-dependent enzyme, catalyzes the conjugation of biotin derivatives onto proteins ([@B65]; [@B39]).

Analytical Methods for Characterization of PEGylated Proteins {#s3}
=============================================================

The evidence indicates that the use of PEG to improve the properties of biopharmaceuticals or diagnostic agents will increase. This is supported by the growing number of proposals in clinical evaluation each year. In order to achieve high-quality products, it is necessary to take into account the implementation of accurate methods for the analysis of some parameters that provide a higher level of characterization of the molecule under study. It is important to note that none of the techniques on their own allows for the most complete characterization of the PEGylated proteins, but in many cases the combination of these is necessary to obtain more accurate results. This section provides an overview of the most frequently used analytical methods for the characterization of PEGylated peptides and proteins.

High-Performance Liquid Chromatography--Mass Spectrometry {#s3_1}
---------------------------------------------------------

High-performance liquid chromatography (HPLC) has been used for the separation and quantitation of free PEG and its PEGylated-protein form (PEG-conjugate). Some features of the PEGylated protein such as conjugate molecular weight, polymer mass distribution, or the degree and sites of PEGylation can be measured by HPLC methods. Lee et al., using SEC (size-exclusion chromatography) and RP-HPLC (reversed phase-high-performance liquid chromatography) mapping, assessed N-terminal PEGylated EGF, demonstrating the formation of a PEGylated macromolecule and that PEGylation occurred at the N-terminal position, respectively ([@B92]). Also, Brand et al. performed the separation of N-terminal PEGylated retargeted tissue factor tTF-NGR by using HPLC-based gel filtration, revealing pure elution fractions with the mono-PEGylated protein, which were represented by one clear band in SDS-PAGE and Western blotting ([@B9]). Although generally useful, the HPLC conditions and detection method must be improved for each compound based on the specific properties of the conjugated proteins.

To improve HPLC performance in the characterization of PEGylated proteins and to provide a more detailed characterization, the solution of coupling liquid chromatography to mass spectrometry was adopted. For decades, mass spectrometry (MS) has been the technique of choice for PEGylated protein characterization in terms of accurate average molecular weight and degree of PEGylation ([@B68]). A comparison of PEGylated and un-PEGylated counterparts by MS and peptide mapping is used to identify and quantify PEGylation sites and characterize impurities that occasionally go undetected by simpler techniques ([@B17]). Collins et al. performed N-terminal amine PEGylation to stabilize oxytocin formulations for prolonged storage. Conjugation was confirmed by Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight (MALDI-TOF) MS, where a clear shift in molecular weight was observed in the MALDI-TOF spectrum from the NHS ester polymer to the polymer-peptide conjugate ([@B28]). In another study conducted by Qin et al. following MALDI-TOF MS, PEG modification sites were determined through comparative analysis of peptide mapping between rhGH (recombinant human growth hormone) and PEG-rhGH. The use of MS makes it possible to discriminate positional isomers, with PEGylation sites potentially located at the N-terminus and nine lysine residues of rhGH ([@B140]). However, the exact determination of the PEG attachment site(s) continues to be highly challenging, especially in a mixture composed of products with differing degrees of PEGylation ([@B49]). On the other hand, ESI-TOF has overcome some disadvantages related to polydispersion and the overlapping protein charge pattern of PEGylated proteins ([@B42]). Furthermore, ESI-MS is preferred to MALDI due to automated workflow and reduced sample preparation time ([@B68]). Several studies have reported applying the approach of the line-up of liquid chromatography to MS (LC-MS) for the sensitive quantitation of free PEG in biological fluid samples ([@B133]; [@B204]) or tissues ([@B55]), as well as clear detection and identification of the positional isomers formed upon PEGylation ([@B49]; [@B163]), obtaining significant structural information in a heterogeneous sample of PEGylated proteins ([@B112]; [@B125]), among others.

Dynamic Light Scattering {#s3_2}
------------------------

Dynamic light scattering (DLS) is an additional technique also convenient for the molecular weight evaluation of PEGylated proteins, as it can measure the molecular radii of the samples ([@B88]; [@B54]), and discriminate between linear and branched PEGs ([@B187]). This method, among others, was used by Vernet et al. in 2016 to assess the first large-scale study with the site-specific mono-PEGylation of 15 different proteins and characterization of 61 entities in total ([@B183]). In addition, Khameneh et al. conducted a study in which site-specific PEGylated hGH was prepared by using microbial transglutaminase. Physicochemical properties, size and zeta potentials of native and PEGylated hGH, were evaluated by DLS, indicating that the size and zeta potentials of the protein were increased and decreased respectively by PEGylation, enhancing the stability of the protein ([@B74]). Recently, Meneguetti et al. applied DLS for the characterization of a novel N-terminal PEGylated asparaginase, showing that the PEGylation of ASNase caused an increase in the hydrodynamic diameter of the protein related to the increase in the amount of PEG attached to the protein ([@B109]). The DLS approach has been used in the characterization not only of PEGylated proteins, but also of PEGylated organic nanotubes, revealing that PEGylation dramatically improves the dispersibility of the nanotubes in saline buffer ([@B33]). Despite its wide use in the characterization of the hydrodynamic radius of PEGylated proteins, this methodology presents certain disadvantages in its application, such as the presence of large particles that can also be detected during the analysis; low resolution when the populations are close in size or a highly polydispersed sample; light absorption by the dispersant can interfere with detection because of their viscosity as well as the density of the particles. These are important parameters to take into account when carrying out this type of analysis.

Nuclear Magnetic Resonance {#s3_3}
--------------------------

^1^H nuclear magnetic resonance (NMR) spectroscopy is useful to quantify PEGylated species in complex biological fluids with advantages of time and simplicity in the sample preparation ([@B5]). The application of this technique for the structural characterization of conjugates with PEG ([@B79]) has been being useful in the quantitative determination of the degree of PEGylation ([@B205]), the assessment of the higher-order structure of PEGylated therapeutic proteins ([@B18]; [@B64]) or even the behavior of free PEG in serum samples ([@B75]). More recently, solid state NMR has been used for the structural characterization of large PEGylated proteins such as asparaginase ([@B52]; [@B20]). The combination of NMR with other techniques such as LC-MS/MS has enabled the accurate quantification of isobaric glycan structures, even in the picomolar order ([@B192]), an approach that could be used for a better characterization of high complexity PEGylated molecules.

Immunoenzymatic Assays {#s3_4}
----------------------

Enzyme-linked immunosorbent assay (ELISA) is a powerful tool for measuring the concentration of PEGylated proteins in serum samples ([@B189]). This technique permits the study of the effects of PEGylation in protein immunogenicity as well as the anti-PEG immune response ([@B187]). While direct ELISA has the advantage of lacking only one specific antibody for compound detection, it cannot distinguish between PEGylated and unPEGylated proteins ([@B16]). On the other hand, sandwich or indirect ELISA employs two antibodies: one to capture the analyte on a solid surface and a second to determine the concentration of the captured analyte ([@B45]). Bruno et al. used a quantitative sandwich ELISA to analyze the pharmacokinetics of Pegasys and PEG-Intron using two mouse monoclonal antihuman IFN-α antibodies that recognize different epitopes of IFN-α ([@B12]), and a similar ELISA was used for the measurement of Neulasta^®^ ([@B148]) and Mircera^®^ ([@B106]). Su et al. produced second-generation monoclonal antibodies attached to PEG (AGP4/IgM and 3.3/IgG) that also bind to the repeating subunits of the PEG backbone, but with greater affinity than those of first-generation AGP3 and E11 ([@B172]). Since then, they have produced a range of specific anti-PEG IgG and IgM monoclonal antibodies for use in ELISA, FACs, IHC, and flow cytometry, which can be found under anti-PEG in the Institute of Biomedical Sciences at Academia Sinica, Taiwan.

Bioinformatics Methods {#s3_5}
----------------------

With the advent of the era of bioinformatics, computational methods have been effectively employed for an easier designing, engineering, and characterization of proteins, which supports experimental methodologies and, in many cases, saves time and materials. At present, computational analysis is highly recommended to select the proper position on the protein for site-selective PEGylation ([@B150]). In 2013 Mu et al. conducted a bioinformatics study in which four forms of PEGylated staphylokinase obtained by site-specific conjugation of PEG to the N- and C-termini of SK, respectively, were structurally evaluated to provide greater molecular insight into the interaction between the PEGylated protein and its receptor ([@B121]). The results suggested that the PEG polymer wraps around the protein providing steric shield, and this effect depends on the PEG chain length and PEGylation site of the protein ([@B150]). Also, [@B115] applied computational and non-glycosylated systems to define an artless methodology for site-selective (cysteine) PEGylation of erythropoietin analogs. The results showed that using an *in silico* approach together with the experimental methodologies can be a strategy to optimize the parameters of PEGylation ([@B115]). Recently, Xu et al. (2018) used interferon (IFN) as a representative model system to characterize the molecular-level changes in IFN introduced by several degrees of PEGylation through molecular dynamics simulations. The simulations generated molecular evidence directly linked to improved protein stability, bioavailability, retention time, as well as the decrease in protein bioactivity with PEG conjugates, providing an important computational approach in the improvement of PEGylated protein drug conjugates and their clinical performance ([@B201]). However, and in spite of the advances obtained in this field, there are still some drawbacks that must be solved, such as the computational cost in terms of infrastructure, and many times, it could be hard to explain what the biological or clinical meaning of features identified using bioinformatics analysis.

Recent Approaches in the Site-Selective Conjugation of Proteins {#s4}
===============================================================

The chemistry of natural amino acids has been a highly exploited approach in the bioconjugation of proteins. However, there is often poor control over the site and various modifications and incompatibilities with complex mixtures or living systems ([@B144]). Since the manipulation of proteins is at the core of biochemical research, the search for new strategies in efficient and specific bioconjugation has been an objective developed by the scientific community through protein engineering. These strategies include for example the SpyTag/SpyCatcher system.

The Spytag/Spycatcher System {#s4_1}
----------------------------

The *SpyTag/SpyCatcher* system allows the specific and covalent conjugation of proteins through two short polypeptide tags ([@B206]). The larger partner, the SpyCatcher, adopts an immunoglobulin-like conformation that specifically binds the SpyTag (γ-carbon of Asp-117), leading the formation of an extremely resistant intermolecular bond between two amino acid side chains ([@B50]). In this extremely fast method, no exogenous enzymes need to be added or removed ([@B41]) and despite its recent description, this system has already been used in the production of synthetic vaccines ([@B11]), thermo-stable enzymes ([@B160]; [@B190]), and other applications ([@B40]; [@B34]; [@B90]). Take advantage of this system, Gilbert et al. described how the XynA enzyme was genetically encoded to covalently conjugate in culture media, providing a novel and flexible strategy for protein conjugation exploiting the substantial advantages of extracellular self-assembly ([@B50]). Recently, Cayetano-Cruz et al. published a study in which the α-glucosidase Ima1p enzyme of *Saccharomyces cerevisiae* was attached to the surface of virus-like particles (VLPs) of parvovirus B19 using the SpyTag/SpyCatcher system. This approach made it possible to obtain a more thermostable enzyme and the modified VLPs were also able to act on glycogen. Hence, these particles may be developed in the future as part of the therapy for the treatment of diseases caused by defects in the human acid α-glucosidase ([@B19]). SpyCatcher is large and may be difficult to attach to polymers; therefore, the final product contains a large SpyCatcher protein sequence ([@B206]). It could be a reason why no study to date has been reported using this system to modify proteins with PEGs. However, this is a promising mechanism to create PEGylated proteins, taking advantage of the fact that SpyTag can be placed at the N-terminus, at the C-terminus and at the internal positions of a protein ([@B206]), and previously bound, for instance, to the polymers (PEG) being conjugated.

Ring Opening Polymerization {#s4_2}
---------------------------

Ring opening polymerization (ROP) is a reaction, in which the terminal end of a polymer chain acts as a reactive center where additional cyclic monomers can react by opening its ring system, forming a longer polymer chain ([@B69]) with the occurrence of two main reactions: initiation and growth ([@B134]). In 2013, Spears et al. used the approach of ROP for first time for the *in situ* controlled branching of polyglycidol and formation of BSA-glycidol bioconjugates with "PEG-like" arms ([@B168]; [@B139]). Since then, ROP has been used as a methodology to modify various molecules as well as to obtain different varieties of polymers. Ma et al. prepared a cross-linked fluorescent polymer through ROP and performed a subsequent ring opening PEGylation with 4-arm PEG-amine, yielding polymeric nanoparticles in aqueous solution with hydrophilic PEG groups covered at the surface ([@B104]). Also, [@B175] developed smart polymeric materials based on biomimetic PEGylated polypeptoids by combining ring-opening polymerization and a post-modification strategy ([@B175]). Furthermore, the usefulness of this approach has also been established in the preparation of PEGylated and fluorescent nanoprobes for biomedical applications ([@B186]; [@B202]) and the development of polymeric gene vectors with high transfection efficiency and improved biocompatibility ([@B198]). All this demonstrates the potential that ROP could have in the design of PEGylated proteins of biopharmaceutical interest or other molecules used in the diagnosis of different diseases.

Click Chemistry {#s4_3}
---------------

Click chemistry is another method widely used for PEG attachment to proteins for different purposes ([@B72]; [@B96]; [@B98]; [@B200]; [@B67]; [@B102]). Here, azide and alkyne groups react selectively with each other in the presence of Cu^1+^ as the catalyst ([@B149]) through the initial reaction of reduced thiols with a maleimide compound containing a click-reactive alkyne moiety. Then, a large PEG molecule containing a complementary click-reactive azide moiety is selectively conjugated to the click-tagged thiols ([@B182]). This method is versatile, fast and simple to use, easy to purify, site-specific, and gives high product yields ([@B63]); however, its drawback is related to the toxicity of copper, even in small amounts. This could limit the development of pharmaceuticals using this methodology; as a result, PEGylation *via* copper-free click reaction has gained more attention nowadays ([@B32]; [@B82]; [@B102]). The reaction conditions are extremely mild and do not cause protein denaturation, nor are any metals, reducing agents or ligands required.

Non-Covalent PEGylation {#s4_4}
-----------------------

Non-covalent PEGylation is an innovative approach in which a chemical reaction between protein and PEG is avoided ([@B145]). It is based on the mechanisms of hydrophobic interactions ([@B122]; [@B123]; [@B124]), ionic interactions ([@B76]), protein polyelectrolyte complex ([@B86]; [@B87]), or chelation ([@B111]). The main advantage of this technique is that it eliminates a potential loss of product due to additional purification processes ([@B145]). However, the release of the protein during storage is an important shortcoming for this approach ([@B151]).

Concluding Remarks {#s5}
==================

The covalent attachment of peptides and proteins to polyethylene glycol remains a preferred method for modifying the pharmacokinetic and immunological properties of therapeutic molecules, supported not only by the introduction of PEGylated drugs on the market but also by the increasing number of currently ongoing clinical studies. The chemical versatility of polyethylene glycol derivatives enables the synthesis of various PEGylated protein structures, with a trend to target-specific amino acid residues located at the terminal ends (N or C-terminus) of the peptides or protein of interest, which contributes to obtaining homogeneous and well-defined conjugates. These site-selective modifications must preserve the biological activity of the PEGylated molecule. As part of the development of the science of PEGylation, new methods continue to be implemented based on new approaches, as well as faster and more efficient techniques, such as enzymatic ligation or the development of bio-orthogonal chemistry. As the number and location of PEG chains attached to a protein can affect its activity, it is critical to uncover these important structural details. Thus, strong analytical methods must be developed, allowing for a qualitative and quantitative characterization with a greater degree of robustness and accuracy. In this sense, the computational tools (predictive models based on molecular dynamics) are a great help in clarifying interactions, binding sites or stability of PEGylated proteins in the unending search for and design of new, more effective biopharmaceuticals.
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